Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics

The safety, pharmacokinetics, and antitumor activity of the multikinase inhibitor regorafenib in Japanese patients was assessed in this multicenter, single-arm, phase I trial. Fifteen patients with treatment-refractory advanced solid tumors received regorafenib 160 mg once daily for the first 3 week...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Sunakawa, Yu, Furuse, Junji, Okusaka, Takuji, Ikeda, Masafumi, Nagashima, Fumio, Ueno, Hideki, Mitsunaga, Shuichi, Hashizume, Kensei, Ito, Yuichiro, Sasaki, Yasutsuna
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Springer US 2013
Onderwerpen:
Phase I Studies
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3913857/
https://ncbi.nlm.nih.gov/pubmed/23553067
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-9953-8
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items